KV gets new life from FDA approval; Salix snaps up Relistor from Progenics;

 @FiercePharma: Pharma suffers on reform, expecting gain later. Story | Follow @FiercePharma

> K-V Pharmaceutical, which had been barred from making and marketing its own drugs, got a huge boost as the FDA approved its drug to reduce the risk of preterm birth. K-V release | Item

> Progenics Pharmaceuticals sold the rights for its constipation shot Relistor to Salix Pharmaceuticals for up to $150 million--within two months of former partner Pfizer's returning it. Report

> A Roche executive told Turkish media that downward pricing pressures from that nation's government may force the drugmaker to reconsider selling some products in the country. News

> Heparin maker Scientific Protein Laboratories says it has resolved "many of the issues" addressed in a recent manufacturing warning letter from the FDA. Article

> Pfizer Japan and Takeda Pharmaceutical extended their co-promotion deal in Japan for the rheumatoid arthritis drug Enbrel (etanercept), and they agreed to co-promoted the experimental anti-inflammatory drug tofacitinib. Report

> Drug wholesaler AmerisourceBergen reported quarterly earnings that topped expectations as it benefited from an increasing number of generic drug launches. News

> New guidance from U.K. health officials says drug manufacturers should keep some "buffer" inventory on hand to make sure they can keep supplies coming during fluctuations in demand. Item

Biotech News

@FierceBiotech: GSK's Witty: We're committed to Britain. Article | Follow @FierceBiotech

@JohnCFierce: So, FYI, I understand that Blair's speech at BIO will be open to the biotech press, tho more details to come. That's all I have right now| Follow @JohnCFierce

> Sanofi and Genzyme zero in on final merger pact. Item 

> AZ's oral prostate cancer drug fails another Ph3 trial. News 

> Biotechs braving stormy IPO waters to raise cash. Report 

> Optimer lands $224M licensing pact for promising antibiotic. Article 

> Daiichi shuffles R&D programs in global restructuring. Story

Biotech IT News

> Vendor challenges NCI-built informatics platform. Article 

> Merck taps CA Technologies for compliance upgrade. News 

> Duke/Potti data probe taking positive turn. Story 

> Grey's Anatomy hospital makes poor trial site. Report

> Oracle teams on secondary use of data. Item

Medical Device News

> In new healthcare world, are diagnostics king? News

> Danaher to buy Beckman Coulter for $83.50 per share. Report

> CareFusion sells ISP unit to Medline for $130M. Story 

> Cellnovo lands $48M for diabetes management system. Article 

> Brown targets device tax in bill. Item 

> St. Jude pipeline looks promising for future. Story

> Ex-Home Diagnostics CEO faces insider trading charges. Report 

And Finally... HHS's Office of Inspector General has a first-ever list of the most-wanted health-care fugitives, featuring 10 of the 170 folks wanted on health fraud and abuse charges. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.